![1.jpg 1.jpg](/SupplyImg/2023-12-06/6383747992038223638082784.jpg)
TSLP分子信息
英文名称:Thymic stromal lymphopoietin
中文名称:胸腺基质淋巴细胞生成素
靶点别称:Thymic stromal lymphopoietin,TSLP
物种:Human / Mouse / Cynomolgus / Rat
属性:Protein
标记:Biotin-labeled / Unconjugated
内毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
无菌(Sterility)
The sterility testing was performed by membrane filtration method.
支原体(Mycoplasma)
Negative.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 24 months in lyophilized state;
2. -70°C for 24 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg/2023-12-06/6383747993084983501349084.jpg)
![3.jpg 3.jpg](/SupplyImg/2023-12-06/6383747993385800711145495.jpg)
TSLP分子背景
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.
TSLP产品用户评价
![4.jpg 4.jpg](/SupplyImg/2023-12-06/6383747994177746012389206.jpg)
关键字: TSLP;TSLP蛋白;TSLP重组蛋白;TSLP抗原;小鼠TSLP;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。